The direct offering of shares by BioCardia is likely to have a dilutive effect on the current shareholders, which could lead to a short-term negative impact on the stock price. However, the capital raised may be used to fund operations or growth initiatives, which could be beneficial in the long term. The confidence level is high due to the direct correlation between share offerings and stock dilution.